Journal of Clinical Oncology - ASCO Publications
WEBSep 9, 2024 — A world where cancer is prevented or cured. Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is …
ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
WEBFor more information on these guidelines, including information about planned guidelines, please access the ASCO.org guidelines page. Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. Guidelines can address specific clinical situations (disease-oriented) or use of approved medical ...
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
WEBOct 17, 2022 — Perioperative chemotherapy is recommended for a total preoperative and postoperative duration of 6 months, on the basis of total duration of chemotherapy in the EORTC 40983 trial. 64. Table 10. Perioperative Chemotherapy Versus Surgery Alone for Patients With Liver Metastases From Colorectal Cancer 22. Open in viewer.
Journal of Clinical Oncology: Vol 42, No 28 - ASCO Publications
WEBAmerican Society of Clinical Oncology. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2024 American Society of Clinical Oncology
ASCO Annual Meeting | ASCO Daily News
WEBJune 19, 2024. Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers. Breast Cancer.
Evidence-Based Management of Oral Mucositis | JCO Oncology …
WEBFeb 3, 2020 — The morbidity of oral mucositis includes pain, nutritional compromise, and infection risk, which potentially result in breaks or dose reductions in cancer therapy. Historically, management was focused mainly on pain control and nutritional support. However, evidence-based clinical practice guidelines for oral and GI mucositis were …
Management of Immune-Related Adverse Events in Patients …
WEBImmunotherapy has revolutionized the treatment of many different types of cancers. Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) work by preventing the receptors and ligands from binding to each other, thereby disrupting signaling so that …
Management of Cancer Therapy–Associated Oral Mucositis
WEBFeb 3, 2020 — Abstract. Mucositis is a common and feared complication of anticancer therapy that can affect up to 90% of certain populations of patients with cancer. Even seemingly uncomplicated mucositis, which is often self-limited, can result in intense patient discomfort and decline in quality of life. Severe mucositis can be complicated by …
Recent Advances in the Management of Metastatic Prostate Cancer
WEBIn 2021, it is estimated that 26% of new noncutaneous cancer cases will be because of prostate cancer resulting in 11% of cancer-related deaths in the United States, making it the most common malignancy in men and the second leading cause of cancer mortality. 1 Following onset of metastatic disease, the disease is invariably fatal with a 5-year …
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
WEBIn the United States, it is estimated that between 8% and 10% of patients with cancer will develop brain metastases representing approximately 200,000 new patients with brain metastases every year. 1 The point prevalence of brain metastases on initial diagnosis varies widely between different cancer histologies. For example, the incidence …
Skip to content